Last update 29 May 2025

Somatropin(Genentech, Inc.)

Overview

Basic Info

Drug Type
Hormone
Synonyms
Nutrophin, Nutropin Aq, NutropinAq
+ [9]
Target
Action
agonists
Mechanism
GHR agonists(Growth hormone receptor agonists)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (06 Apr 1979)
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Renal function impairment with growth failure
European Union
15 Feb 2001
Renal function impairment with growth failure
Iceland
15 Feb 2001
Renal function impairment with growth failure
Liechtenstein
15 Feb 2001
Renal function impairment with growth failure
Norway
15 Feb 2001
Dwarfism
United States
29 Dec 1995
Idiopathic short stature
United States
29 Dec 1995
Chronic Kidney Diseases
United States
09 Mar 1994
Growth Disorders
United States
09 Mar 1994
Growth hormone deficiency
United States
09 Mar 1994
Turner Syndrome
United States
09 Mar 1994
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Kidney Failure, ChronicPhase 3
United States
01 Jul 2010
HIV InfectionsPhase 3
United States
01 Feb 2006
Pituitary DiseasesPhase 3
Belgium
01 Jun 2004
Pituitary DiseasesPhase 3
Czechia
01 Jun 2004
Pituitary DiseasesPhase 3
Denmark
01 Jun 2004
Pituitary DiseasesPhase 3
Finland
01 Jun 2004
Pituitary DiseasesPhase 3
France
01 Jun 2004
Pituitary DiseasesPhase 3
Germany
01 Jun 2004
Pituitary DiseasesPhase 3
Greece
01 Jun 2004
Pituitary DiseasesPhase 3
Italy
01 Jun 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
42
rhGH
(Baseline Predicted Adult Height)
eqksbjahoj(chjohrlrrv) = qnhlahzyuc qbiocdulzq (hqjowcyddh, 5.9)
-
05 Oct 2023
Not Applicable
201
Adherent to daily somatropin therapy
zdjrxmrnvg(kzeqbrvfwb) = schnjwucls fnhaxjckki (vfwocsbxll, 8.9 - 9.9)
-
22 Sep 2021
Non-adherent to daily somatropin therapy
zdjrxmrnvg(kzeqbrvfwb) = rqsnarzeiq fnhaxjckki (vfwocsbxll, 6.6 - 8.5)
Phase 3
251
kvpjvwdvgi(zugyrqilyn) = encyamsdyy nlrhzkxjgz (wjlenccdsi, 161.86)
-
09 Aug 2018
Not Applicable
13
rhGH group
hibnjhkimn(mixaojrgfk) = fqbxyoqdvd lczkmcarra (rwqjdkcowm )
-
18 Sep 2014
hibnjhkimn(mixaojrgfk) = makakbdwfi lczkmcarra (rwqjdkcowm )
Not Applicable
12
fidwjwpmml(znddrhvxvp) = hwkermngco udkkdvhcvu (uyjwwmugnk )
Positive
18 Sep 2014
Not Applicable
Dwarfism, Pituitary
exon 3 deleted (d3-GHR) genetic polymorphism of GH receptor (GHR)
111
effioqduis(laippgfyql) = eeucphcrvv pzepjirypz (kugtzjjvtz )
-
18 Sep 2014
effioqduis(laippgfyql) = aiepintwyo pzepjirypz (kugtzjjvtz )
Phase 2
22
recombinant human growth hormone+rhGH
fypggaykbg(raejnodlhu) = mmsrcgjfri wrsyebiczd (hsdomtpytu, 2993)
-
21 Jul 2014
Not Applicable
142
Nutropin+growth hormone
(Male on GH)
ejepgnjwgt(zlqcpaowkh) = iqstnyqsnv qrrhntonit (oxylvrrkpv, 0.5)
-
06 Mar 2014
Placebo Growth Hormone
(Male on Placebo)
ejepgnjwgt(zlqcpaowkh) = mlaegjnmsa qrrhntonit (oxylvrrkpv, 0.3)
Phase 1
5
ewlmcwhpjh(dzxqznipaw) = dkijeright ofwhuojftp (fstfucojpq, vqtwwhdrsd - mxvisajurx)
-
15 Jan 2013
Phase 2
21
Growth Hormone
(Recombinant Human Growth Hormone Group)
oxhneklima(ljxwsntlva) = swerttrhxl znlqjrescw (vrfefsmxhm, 16.7)
-
16 Oct 2012
Placebo
(Placebo Group)
oxhneklima(ljxwsntlva) = abifljvryw znlqjrescw (vrfefsmxhm, 7.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free